Pokryszka J, Primas C, Stadlmann M, Gerold N, et al. Post-induction serum vedolizumab levels are not associated with better maintenance outcomes in patients with Crohn's disease. Z Gastroenterol 2026 Jan 12. doi: 10.1055/a-2744-5136.
PMID: 41525786